Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Docetaxel, Cisplatin, and Radiation in Resectable Esophageal Cancer
NCT00445861Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 2007
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in esophageal cancer, sponsored by Swiss Group for Clinical Cancer Research. Started Jan 2007; status: completed.
02
Drugs
KL-140
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00445861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445861.